T. Rowe Price Associates
MAZE

T. Rowe Price Associates’s Maze Therapeutics MAZE Stock Holding History

T. Rowe Price Associates’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.96M Buy
132,870
+10,175
+8% +$267K ﹤0.01% 1685
2026
Q1 		$3.66M Buy
122,695
+6,984
+6% +$308K ﹤0.01% 1561
2025
Q4 		$4.79M Buy
115,711
+105,237
+1,005% +$3.62M ﹤0.01% 1399
2025
Q3 		$272K Buy
+10,474
New +$177K ﹤0.01% 2648

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

T. Rowe Price Associates's MAZE Position: Q2 2026 in Review

T. Rowe Price Associates increased its Maze Therapeutics (MAZE) stake by 8.3% in Q2 2026, buying an estimated $267K and bringing the position to 132,870 shares worth $3.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1685.

T. Rowe Price Associates first reported a position in MAZE in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.79M in Q4 2025. 161 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • T. Rowe Price Associates held 132,870 shares of Maze Therapeutics worth $3.96M as of Q2 2026.
  • T. Rowe Price Associates bought 10,175 Maze Therapeutics shares in Q2 2026, an estimated $267K.
  • Maze Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1685 holding.
  • T. Rowe Price Associates first reported a position in Maze Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • T. Rowe Price Associates's Maze Therapeutics position peaked at $4.79M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.